Alamar Biosciences, Inc. quarterly report, Q2 FY2026

Business Context and Reporting Period

Company: Alamar Biosciences, Inc. (ALMR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Alamar is a commercial-stage proteomics company developing the ARGO HT System, a high-throughput precision proteomics platform for early disease detection. The company sells instruments, consumables, and services to research institutions, biopharmaceutical companies, and contract research organizations.
Key Event: The company completed its Initial Public Offering (IPO) on April 20, 2026, raising approximately $197.8 million in net proceeds. A reverse stock split (1-for-2.418) was effected in April 2026.

Key Financial Metrics

Metric (in thousands) Three Months Ended
June 30, 2026
Three Months Ended
June 30, 2025
Six Months Ended
June 30, 2026
Six Months Ended
June 30, 2025
Total Revenue $29,427 $16,162 $55,462 $29,253
Gross Profit $17,718 $8,581 $32,175 $14,970
Gross Margin 60.2% 53.1% 58.0% 51.2%
Net Loss $(13,199) $(7,023) $(34,524) $(14,682)
Net Loss Per Share (Basic/Diluted) $(0.22) $(0.62) $(0.97) $(1.30)
Cash, Cash Equivalents & Short-Term Investments $250,052 (as of June 30, 2026)
Accumulated Deficit $(203,299) (as of June 30, 2026)

Material Changes vs. Prior Period

  • Revenue Growth: Total revenue increased 82% year-over-year for the quarter and 90% for the six-month period. This was driven by a 35% increase in instrument sales and a 147% increase in consumables revenue, reflecting an expanding installed base (over 100 instruments as of Dec 31, 2025).
  • Operating Expenses: Operating expenses rose significantly, increasing 89% for the quarter and 85% for the six-month period. Selling, General, and Administrative (SG&A) expenses increased 129% and 119% respectively, primarily due to headcount growth and professional services costs associated with the IPO and public company operations.
  • Non-Cash Charges: The company recorded a loss on the remeasurement of convertible notes of $1.4 million for the quarter and $10.0 million for the six months ended June 30, 2026, prior to their conversion into common stock upon the IPO.
  • Liquidity: Cash and cash equivalents increased from $30.0 million at year-end 2025 to $133.0 million at June 30, 2026, bolstered by IPO proceeds and convertible note issuances.

Guidance, Outlook, and Risks

  • Outlook: Management expects to continue incurring significant operating losses in the near term as it invests in R&D, manufacturing expansion, and commercialization. The company plans to submit the ARGO HT/DX instrument for FDA marketing authorization in 2027.
  • Stock-Based Compensation: Full-year 2026 stock-based compensation is expected to range between $13 million and $15 million.
  • Seasonality: The company anticipates seasonal purchasing patterns, with higher instrument purchases and consumable pull-through expected in the fourth quarter due to customer budget cycles.
  • Key Risks:
    • Profitability: The company has incurred losses since inception and may not achieve sustained profitability.
    • Regulatory: Current products are "Research Use Only" (RUO). Future clinical products require FDA approval, which is uncertain and costly.
    • Intellectual Property: Ongoing litigation with Olink Proteomics regarding patent infringement (U.S. Patent No. 7,883,848). While an Inter Partes Review (IPR) found the patent claims not unpatentable, Alamar has appealed this decision, and district court litigation remains pending.
    • Supply Chain: Dependence on single-source suppliers for critical components and antibodies.

Investor Verification Checklist

  • Installed Base Growth: Verify the current number of ARGO HT instruments installed and the average annual consumable pull-through per instrument to assess recurring revenue potential.
  • Customer Concentration: Review the percentage of revenue derived from academic institutions vs. biopharmaceutical companies, noting the reliance on government funding (NIH grants) for academic customers.
  • Legal Proceedings: Monitor the status of the appeal regarding the Olink Proteomics patent litigation and the outcome of the pending motion to dismiss in the Delaware district court.
  • Manufacturing Capacity: Assess the company's ability to scale in-house consumable manufacturing and manage third-party instrument production to meet demand without quality issues.
  • Cash Burn Rate: Evaluate the runway provided by the $250 million in unrestricted cash against the projected increase in operating expenses and R&D investments.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.